Cardiol Therapeutics (NASDAQ:CRDL) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL) in a research report report published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 target price on the stock.

Cardiol Therapeutics Stock Performance

NASDAQ:CRDL opened at $1.24 on Monday. The stock has a market cap of $102.44 million, a P/E ratio of -3.18 and a beta of 0.98. The firm’s fifty day simple moving average is $1.05 and its 200 day simple moving average is $1.22. Cardiol Therapeutics has a twelve month low of $0.77 and a twelve month high of $3.12. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. As a group, research analysts predict that Cardiol Therapeutics will post -0.33 EPS for the current year.

Institutional Trading of Cardiol Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Cardiol Therapeutics in the fourth quarter valued at $61,000. Envestnet Asset Management Inc. bought a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $398,000. Atria Investments Inc bought a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $174,000. PVG Asset Management Corp bought a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at $624,000. Finally, Tejara Capital Ltd boosted its holdings in shares of Cardiol Therapeutics by 75.9% during the 4th quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company’s stock valued at $3,988,000 after buying an additional 1,344,167 shares in the last quarter. Institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.